Bionomics Limited : CEO UPDATE AND US INVESTOR PRESENTATION

CEO UPDATE AND US INVESTOR PRESENTATION 09-Jan-2012

9 January 2012: Bionomics Limited (ASX:BNO) today announced its CEO, Dr Deborah Rathjen, will present a company update at the Biotech Showcase 2011 in San Francisco, USA. The presentation highlights the progress of Bionomics' proprietary and partnered discovery and development pipeline including the recent BNC210 partnership with Ironwood Pharmaceuticals. The presentation will take place at 3.00pm in the Mission II Room, Parc 55 Wyndham, Union Square, San Francisco.

As part of activities surrounding the 30th JP Morgan Healthcare Conference, briefings will also be given to US institutional investors and pharmaceutical companies.

The presentation can be found on Bionomics' website

Enquiries:
Bionomics Limited
Dr Deborah Rathjen
CEO & Managing Director
[phone] / 0418 160 425
[e-mail]

Lauren Glaser
The Trout Group
[phone]
[e-mail]

About Bionomics Limited

Bionomics (ASX: BNO) is a leading international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis. BNC105, which is undergoing clinical development for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours.

Bionomics' discovery and development activities are driven by its three technology platforms: Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels). MultiCore® is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX® is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system.

For more information about Bionomics, visit

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of I995. Any statements contained in this press release that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' development candidates BNC105, BNC210, its Merck Serono alliance, its licensing agreement with Ironwood Pharmaceuticals, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings. Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.